Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French Pharmacovigilance Database
European Respiratory Journal · 2025-02 · 65 (2) · 2400756
DOI: 10.1183/13993003.00756-2024 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Respiratory Journal, online erschienen am 07.11.2024. Verfasst von Sophie Yavordios und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adultes de Dijon, Réseau…. Hauptthemen laut MEDLINE: Pharmacovigilance, Lung Diseases, Interstitial, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Drug-induced interstitial lung disease (DI-ILD) is a heterogeneous subgroup of interstitial lung disease (ILD). The number of molecules involved is increasing with time. Due to their low incidence, DI-ILDs may be detected only after a drug has been marketed, notably through adverse drug reaction (ADR) reports to pharmacovigilance centres. The aim of our study was to describe drug-induced diffuse lung disease cases notified to and recorded by the French Pharmacovigilance Database (FPVD), reported clinical pictures and the potentially causal drugs.
Methods
This retrospective study included cases registered in the FPVD from 1 January 1985 to 1 April 2022 which had ADRs coded in MedDRA with a High-Level Group Term “Lower respiratory tract disorders (excluding obstruction and infection)” involving patients aged ≥18 years.
Results
We analysed 7234 cases involving 13 059 suspect medications and 1112 specific molecules. Cases were categorised as serious in 96.7% and death ensued in 13.3%. Males accounted for 54.4% of the cases. Median (range) age was 69 (18–103) years. The most prevalent ADRs were “Interstitial lung disease” (51.0%), “Pulmonary oedema” (acute/non-acute) (15.6%) and “Pulmonary fibrosis” (10.5%). Anti-cancer drugs (31.2%) and cardiovascular drugs (29.1%) were the most prominent therapeutic classes involved, with amiodarone being the most commonly reported suspected drug (10.0%), followed by methotrexate (3.1%).
Conclusion
This study from a large nationwide dataset spanning 37 years is the largest known to date. Drug-induced diffuse lung diseases are serious with a potentially fatal outcome. Accurate diagnoses remain essential to identify the diseases properly and discontinue the culprit drug urgently.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adultes de Dijon, Réseau OrphaLung, Filière RespiFil, CHU Dijon-Bourgogne, Dijon, France.
- INSERM U1231, Labex LIPSTIC and label of excellence from La Ligue Nationale Contre le Cancer, Dijon, France.
- Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
- Regional Pharmacovigilance Centre, François Mitterrand Hospital, University of Burgundy Franche-Comté, Dijon, France.
- Regional Pharmacovigilance Centre of Centre Val de Loire, Department of Pharmacosurveillance, University Hospital of Tours, Tours, France.
- Regional Pharmacovigilance Centre, Hôpital Européen Georges Pompidou, AP-HP, Centre - Université Paris Cité, Paris, France.
ORCID-Profile: Guillaume Beltramo, Philippe Bonniaud
Zitieren
APA
Yavordios, S., Beltramo, G., Freppel, R., Beau Salinas, F., Le Beller, C., Bihan, K., Mouillot, P., Georges, M., Grandvuillemin, A., & Bonniaud, P. (2025). Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French Pharmacovigilance Database. European Respiratory Journal, 65(2), 2400756. https://doi.org/10.1183/13993003.00756-2024
Vancouver
Yavordios S, Beltramo G, Freppel R, Beau Salinas F, Le Beller C, Bihan K, et al. Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French Pharmacovigilance Database. European Respiratory Journal. 2025;65(2):2400756. doi:10.1183/13993003.00756-2024
BibTeX
@article{Yavordios2025,
author = {Yavordios, Sophie and Beltramo, Guillaume and Freppel, Romane and Beau Salinas, Frédérique and Le Beller, Christine and Bihan, Kevin and Mouillot, Pierre and Georges, Marjolaine and Grandvuillemin, Aurélie and Bonniaud, Philippe},
title = {Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French Pharmacovigilance Database},
journal = {European Respiratory Journal},
year = {2025},
volume = {65},
number = {2},
pages = {2400756},
doi = {10.1183/13993003.00756-2024}
}
EUVIMED